litlas
Log inCreate account

Scott M. Wasserman

Active 2002–2020

59
Papers
24,434
Citations
57
h-index
59
i10-index

Citations

Citations per year for Scott M. Wasserman1969: 5 citations1985: 1 citations1997: 1 citations1998: 1 citations2003: 4 citations2004: 20 citations2005: 29 citations2006: 12 citations2007: 7 citations2008: 32 citations2009: 28 citations2010: 14 citations2011: 25 citations2012: 30 citations2013: 139 citations2014: 222 citations2015: 377 citations2016: 323 citations2017: 489 citations2018: 447 citations2019: 1,207 citations2020: 1,112 citations2021: 914 citations2022: 803 citations2023: 610 citations2024: 950 citations2025: 524 citations2026: 33 citations1970–1984: no citations, so these years are not shown1986–1996: no citations, so these years are not shown1999–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,079 citing papers, 20.7% of this breakdownUnited Kingdom: 756 citing papers, 7.5% of this breakdownChina: 583 citing papers, 5.8% of this breakdownItaly: 544 citing papers, 5.4% of this breakdownCanada: 499 citing papers, 5% of this breakdownGermany: 483 citing papers, 4.8% of this breakdownNetherlands: 434 citing papers, 4.3% of this breakdownAustralia: 387 citing papers, 3.8% of this breakdownFrance: 351 citing papers, 3.5% of this breakdownSpain: 277 citing papers, 2.7% of this breakdownSwitzerland: 259 citing papers, 2.6% of this breakdownJapan: 252 citing papers, 2.5% of this breakdown
0%20.7%Other 31.4%

Institutions

Fields

  • Medicine81%
  • Biochemistry, Genetics and Molecular Biology12.2%
  • Immunology and Microbiology3.2%
  • Economics, Econometrics and Finance0.6%
  • Computer Science0.5%
  • Neuroscience0.4%
  • Other2.1%

Topics

  • Lipoproteins and Cardiovascular Health18.7%
  • Diabetes, Cardiovascular Risks, and Lipoproteins6.4%
  • Atherosclerosis and Cardiovascular Diseases4.9%
  • Cancer, Lipids, and Metabolism2.7%
  • Bone health and osteoporosis research2.2%
  • Health Systems, Economic Evaluations, Quality of Life1.9%
  • Other63.2%

Coauthors

All papers

Open in search
  1. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

    Authors: Marc S. Sabatine, Robert P. Giugliano, Anthony Keech, Narimon Honarpour, Stephen D. Wiviott, Sabina A. Murphy, Julia Kuder, Huei Wang, Thomas Liu, Scott M. Wasserman, Peter Sever, Terje R. Pedersen - New England Journal of Medicine 2017 cited by 5,987

  2. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

    Authors: Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano, Erik S.G. Stroes, Estella Kanevsky, Ioanna Gouni‐Berthold, KyungAh Im, Armando Lira Pineda, Scott M. Wasserman, R Češka, М. В. Ежов, J. Wouter Jukema, Henrik Kjærulf Jensen, S. Lale Tokgözoğlu, François Mach, Kurt Huber, Peter Sever, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine - Circulation 2019 cited by 948

  3. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients

    Authors: Stephen J. Nicholls, Rishi Puri, Todd J. Anderson, Christie M. Ballantyne, Leslie Cho, John J.P. Kastelein, Wolfgang Köenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang, Scott M. Wasserman, Robert C. Scott, Imre Ungi, Jakub Podolec, Antonius Oude Ophuis, Jan H. Cornel, Marilyn Borgman, Danielle M. Brennan, Steven E. Nissen - JAMA 2016 cited by 1,154

  4. Romosozumab in Postmenopausal Women with Low Bone Mineral Density

    Authors: Michael R. McClung, Andreas Grauer, Steven Boonen, Michael A. Bolognese, Jacques P. Brown, Adolfo Díez‐Pérez, Bente Langdahl, Jean‐Yves Reginster, José Zanchetta, Scott M. Wasserman, Leonid Katz, Judy Maddox, Yuching Yang, Cesar Libanati, Henry G. Bone - New England Journal of Medicine 2014 cited by 1,235

  5. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

    Authors: Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park, Gaetano Maria De Ferrari, Zbigniew Gaciong, R Češka, Kálmán Tóth, Ioanna Gouni‐Berthold, José López‐Miranda, François Schiele, François Mach, Brian R. Ott, Estella Kanevsky, Armando Lira Pineda, Ransi Somaratne, Scott M. Wasserman, Anthony Keech, Peter S. Sever, Marc S. Sabatine - The Lancet 2017 cited by 677

  6. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    Authors: Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, Frederick J. Raal, Dirk Blom, Jennifer G. Robinson, Christie M. Ballantyne, Ransi Somaratne, Jason C. Legg, Scott M. Wasserman, Robert C. Scott, Michael J. Koren, Evan A. Stein - New England Journal of Medicine 2015 cited by 1,495

  7. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

    Authors: Frederick J. Raal, Evan A. Stein, Robert Dufour, Traci Turner, Fernando Civeira, Lesley Burgess, Gisle Langslet, Russell Scott, Anders Olsson, David Sullivan, G. Kees Hovingh, Bertrand Cariou, Ioanna Gouni‐Berthold, Ransi Somaratne, Ian Bridges, Robert C. Scott, Scott M. Wasserman, Daniel Gaudet - The Lancet 2014 cited by 751

  8. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

    Authors: Dirk Blom, Tomas Hala, Michael A. Bolognese, Michael Lillestol, Phillip D. Toth, Lesley Burgess, R Češka, Eli M. Roth, Michael J. Koren, Christie M. Ballantyne, Maria Laura Monsalvo, Kate Tsirtsonis, Jae Bum Kim, Robert C. Scott, Scott M. Wasserman, Evan A. Stein - New England Journal of Medicine 2014 cited by 713

  9. Cognitive Function in a Randomized Trial of Evolocumab

    Authors: Robert P. Giugliano, François Mach, Kenton H. Zavitz, Christopher E. Kurtz, Kyungah Im, Estella Kanevsky, Jingjing Schneider, Huei Wang, Anthony Keech, Terje R. Pedersen, Marc S. Sabatine, Peter S. Sever, Jennifer G. Robinson, Narimon Honarpour, Scott M. Wasserman, Brian R. Ott - New England Journal of Medicine 2017 cited by 482

  10. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

    Authors: Steven E. Nissen, Erik S.G. Stroes, Ricardo E. Dent‐Acosta, Robert S. Rosenson, Sam J. Lehman, Naveed Sattar, David Preiss, Éric Bruckert, R Češka, Norman E. Lepor, Christie M. Ballantyne, Ioanna Gouni-Berthold, Mary Elliott, Danielle M. Brennan, Scott M. Wasserman, Ransi Somaratne, Rob Scott, Evan A. Stein, for the GAUSS-3 Investigators - JAMA 2016 cited by 511

  11. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

    Authors: Frederick J. Raal, Narimon Honarpour, Dirk Blom, G. Kees Hovingh, Feng Xu, Robert C. Scott, Scott M. Wasserman, Evan A. Stein - The Lancet 2014 cited by 727

  12. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

    Authors: Robert P. Giugliano, Terje R. Pedersen, Jeffrey L. Saver, Peter S. Sever, Anthony Keech, Erin A. Bohula, Sabina A. Murphy, Scott M. Wasserman, Narimon Honarpour, Huei Wang, Armando Lira Pineda, Marc S. Sabatine, on behalf of the FOURIER Investigators - Stroke 2020 cited by 182

  13. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

    Authors: David M. Charytan, Marc S. Sabatine, Terje R. Pedersen, KyungAh Im, Jeong‐Gun Park, Armando Lira Pineda, Scott M. Wasserman, Prakash Deedwania, Anders Olsson, Peter Sever, Anthony Keech, Robert P. Giugliano - Journal of the American College of Cardiology 2019 cited by 203

  14. Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia

    Authors: Jennifer G. Robinson, Bettina S. Nedergaard, William J. Rogers, Jonathan Fialkow, Joel M. Neutel, David Ramstad, Ransi Somaratne, Jason C. Legg, Patric Nelson, Robert C. Scott, Scott M. Wasserman, Robert Weiss - JAMA 2014 cited by 501

  15. Anti-PCSK9 Monotherapy for Hypercholesterolemia

    Authors: Michael J. Koren, Pernille Lundqvist, Michael A. Bolognese, Joel M. Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Robert C. Scott, Scott M. Wasserman, Harold Bays - Journal of the American College of Cardiology 2014 cited by 407

  16. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

    Authors: Sreeneeranj Kasichayanula, Anita Grover, Maurice G. Emery, Megan Gibbs, Ransi Somaratne, Scott M. Wasserman, John P. Gibbs - Clinical Pharmacokinetics 2018 cited by 131

  17. Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

    Authors: Erik S.G. Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts, Éric Bruckert, Leslie Cho, Ricardo Dent, Beat Knüsel, Allen Xue, Robert C. Scott, Scott M. Wasserman, Michael Rocco - Journal of the American College of Cardiology 2014 cited by 527

  18. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment

    Authors: Lotte C.A. Stiekema, Erik S.G. Stroes, Simone L. Verweij, Helina Kassahun, Lisa Chen, Scott M. Wasserman, Marc S. Sabatine, Venkatesh Mani, Zahi A. Fayad - European Heart Journal 2018 cited by 136

  19. Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

    Authors: Evan A. Stein, Narimon Honarpour, Scott M. Wasserman, Feng Xu, Robert C. Scott, Frederick J. Raal - Circulation 2013 cited by 330

  20. Effect of Evolocumab on Coronary Plaque Composition

    Authors: Stephen J. Nicholls, Rishi Puri, Todd J. Anderson, Christie M. Ballantyne, Leslie Cho, John J.P. Kastelein, Wolfgang Köenig, Ransi Somaratne, Helina Kassahun, Jingyuan Yang, Scott M. Wasserman, Satoshi Honda, Daisuke Shishikura, D. Scherer, Marilyn Borgman, Danielle M. Brennan, Kathy Wolski, Steven E. Nissen - Journal of the American College of Cardiology 2018 cited by 142

  21. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

    Authors: Robert P. Giugliano, Nihar R. Desai, Payal Kohli, William J. Rogers, Ransi Somaratne, Fannie Huang, Thomas Liu, Satishkumar Mohanavelu, Elaine Hoffman, Shannon T McDonald, Timothy E Abrahamsen, Scott M. Wasserman, Robert C. Scott, Marc S. Sabatine - The Lancet 2012 cited by 424

  22. Cardiovascular Drug Development

    Authors: Christopher B. Fordyce, Matthew T. Roe, Tariq Ahmad, Peter Libby, Jeffrey Borer, William R. Hiatt, Michael R. Bristow, Milton Packer, Scott M. Wasserman, Ned Braunstein, Bertram Pitt, David L. DeMets, Katharine Cooper‐Arnold, Paul W. Armstrong, Scott D. Berkowitz, Robert C. Scott, Jayne Prats, Zorina S. Galis, Norman Stockbridge, Eric D. Peterson, Robert M. Califf - Journal of the American College of Cardiology 2015 cited by 204

  23. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

    Authors: Gerald F. Watts, Dick C. Chan, Ransi Somaratne, Scott M. Wasserman, Robert C. Scott, Santica M. Marcovina, P. Hugh R. Barrett - European Heart Journal 2018 cited by 147

  24. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

    Authors: Michael J. Koren, Marc S. Sabatine, Robert P. Giugliano, Gisle Langslet, Stephen D. Wiviott, Andrea Ruzza, Yuhui Ma, Andrew Hamer, Scott M. Wasserman, Frederick J. Raal - Journal of the American College of Cardiology 2019 cited by 146